98%
921
2 minutes
20
Objectives: The study was focused on geographical mapping of dengue cases and also to identify the hotspots or high-risk areas of dengue in Delhi.
Design: A retrospective spatial-temporal (ecological) study. Descriptive analysis was used to know the distribution of dengue cases by age, sex, seasons and districts of Delhi. The spatiotemporal analysis was performed using inverse distance weighting and Getis-Ord Gi* statistic to know the geographical distribution and identify the hotspot areas.
Settings: All the confirmed and diagnosed dengue cases (IgM +ve or NS1 Antigen +ve ELISA) recorded by the Municipal Corporation of Delhi for the last 4 years (2015-2018) were collected with their local address. The location of all the dengue cases was geocoded using their address to prepare the spatiotemporal dengue database.
Participants: Record of all the dengue cases (4179) reported for treatment in the hospitals during the past 4 years were extracted and included in the study. Data were not collected directly from dengue patients.
Results: Seasonal occurrence of dengue cases (4179) shows that the cases start emerging in July, peaked in September-October and declined in December. The proportions of dengue cases were recorded high among the males 57.3% compared with females 42.6%, and differences were also recorded in all the age groups with more cases in age groups <15 and 16-30 years. Mapping of the cases reflects the spatial heterogeneity in the geographical distribution. The geomapping of cases indicates the presence of a significantly high number of cases in West, Southwest, South and Southeast districts of Delhi. High-risk areas or hotspots were also identified in this region.
Conclusion: Dengue occurrence shows significant association with age, sex and seasons. The spatial analysis identified the high-risk areas, which can aid health administrators to take necessary action for prevention and better disease management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925904 | PMC |
http://dx.doi.org/10.1136/bmjopen-2020-043848 | DOI Listing |
Interact J Med Res
September 2025
Department of Medicine, MacKay Medical College, New Taipei, Taiwan.
Background: Dengue fever remains the most significant vector-borne disease in Southeast Asia, imposing a substantial burden on public health systems. Global warming and increased international mobility may exacerbate the disease's prevalence. Furthermore, the unprecedented COVID-19 pandemic may have influenced the epidemiological patterns of dengue.
View Article and Find Full Text PDFPLoS Negl Trop Dis
September 2025
División de Inmunología, Programa de Medicina, Facultad de Ciencias de la Salud, Universidad Surcolombiana, Neiva, Huila, Colombia.
Background: Dengue and chikungunya are arboviral diseases with overlapping clinical characteristics. Dengue virus (DENV) is endemic in Colombia, and in 2014/2015, the chikungunya virus (CHIKV) caused an epidemic that resulted in over 350,000 cases. Since then, both viruses have been actively co-circulating.
View Article and Find Full Text PDFNew Microbes New Infect
October 2025
Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Introduction: Dengue fever, the most prevalent arthropod-borne viral disease, causes ∼400 million infections annually. Although thrombocytopenia is commonly associated with dengue, how it evolves in relation to viral load and immune responses remains poorly understood. This study aimed to elucidate platelet-virus-immune interactions in acute dengue by systematically tracking of viral load, platelet parameters, and leukocyte dynamics.
View Article and Find Full Text PDFVirology
September 2025
Department of Medicine, Democritus University of Thrace, Alexandroupolis, Evros, Greece.
Background: Dengue virus (DENV) is a major global health challenge, causing over 7.6 million reported cases in 2024. Neutralizing monoclonal antibodies (NmAbs) have emerged as promising therapeutics to address the limitations of vaccines and lack of antivirals, but their development is complicated by viral diversity, "breathing" dynamics, and antibody-dependent enhancement (ADE).
View Article and Find Full Text PDFJ Travel Med
September 2025
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Background: Although there is a rising trend in both dengue cases and immunocompromised conditions, there is limited research on how common severe dengue is in immunocompromised individuals. This data is key for those advising the ever-increasing numbers of immunocompromised travellers.
Methods: We conducted a systematic review and meta-analysis of studies reporting dengue frequency or outcomes in immunocompromised populations.